These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16220092)

  • 1. Antimicrobial update: Daptomycin.
    Oberholzer CM; Caserta MT
    Pediatr Infect Dis J; 2005 Oct; 24(10):919-20. PubMed ID: 16220092
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
    Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL
    Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections].
    Mathiesen L; Midtvedt T; Solberg CO
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2383-4. PubMed ID: 16998552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
    Eisenstein BI; Oleson FB; Baltz RH
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S10-5. PubMed ID: 20067387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
    Jones RN; Mendes RE; Sader HS
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv17-31. PubMed ID: 21115451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cSSTIs: the role of daptomycin.
    Garau J
    Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
    Hair PI; Keam SJ
    Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and killing effect of citropin 1.1 against gram-positive pathogens causing skin and soft tissue infections.
    Giacometti A; Cirioni O; Kamysz W; Silvestri C; Del Prete MS; Licci A; D'Amato G; Łukasiak J; Scalise G
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2507-9. PubMed ID: 15917557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.
    Sader HS; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2010 Jul; 36(1):28-32. PubMed ID: 20444576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment.
    Cardona AF; Wilson SE
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S69-78. PubMed ID: 26316560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
    Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):351-6. PubMed ID: 16765555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections.
    Kern WV
    Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of bacteraemic isolates of gram-positive cocci to daptomycin and other antimicrobial agents.
    Amsterdam D; Gorzynski EA; Beam TR; Rotstein C
    J Antimicrob Chemother; 1994 May; 33(5):1060-4. PubMed ID: 8089056
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro and in vivo activity of fosfomycin alone and in combination with rifampin and tigecycline against Gram-positive cocci isolated from surgical wound infections.
    Simonetti O; Morroni G; Ghiselli R; Orlando F; Brenciani A; Xhuvelaj L; Provinciali M; Offidani A; Guerrieri M; Giacometti A; Cirioni O
    J Med Microbiol; 2018 Jan; 67(1):139-143. PubMed ID: 29154746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Daptomycin in complicated skin and soft tissue infections].
    Barberán J; Fariñas MC
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():33-7. PubMed ID: 22541973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficient antimicrobial chemotherapy for skin and soft tissue infections].
    Guchev IA; Sidorenko SV; Frantsuzov VN
    Antibiot Khimioter; 2003; 48(10):25-31. PubMed ID: 15004977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.